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Key Clinical Message
Thrombopoietin receptor agonists (TPO-RAs) are used as effective alternative
treatments in ITP patients unresponsive to first-/second-line therapies. TPO-
RAs can also be used to normalize platelet count to safely perform invasive pro-
cedures and chemotherapy, in case of malignancies. In few responsive patients,
TPO-RAs can be suspended maintaining a sustained response.
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Introduction
Primary immune thrombocytopenia (pITP) is an autoim-
mune disorder characterized either by an increased periph-
eral platelets clearance or by a decreased platelets
production. The goal of pITP therapy is to reach and main-
tain a safe platelet level to avoid bleedings. International
guidelines recommend corticosteroids and/or high-dose
immunoglobulin as first-line treatment, while splenectomy
as a second-line therapy. In case of contraindication or
refractoriness to splenectomy, rituximab or other immuno-
suppressants and the new thrombopoietin receptor ago-
nists (TPO-RAs), romiplostim and eltrombopag, are
considered alternative treatments [1, 2]. In Europe, TPO-
RAs have been approved by EMA for the treatment of
chronic pITP patients unresponsive to other therapies.
Case Report with Results
In May 2007, a 61-year-old woman was referred to our
center because of a severe thrombocytopenia (platelet
count 17 9 109/L) and presence of ecchymoses and pete-
chiae. Bone marrow smear examination showed increased
megakaryopoiesis and normal granulopoiesis, erythro-
poiesis, and lymphopoiesis. Other causes of ITP (autoim-
mune conditions, infections, solid or hematologic
neoplasms) were excluded. Therefore, a diagnosis of pITP
was made and the patient started corticosteroid therapy
(prednisone 1 mg/kg/day for 4 weeks) obtaining a com-
plete response (CR) with a platelet count of 160 9 109/L.
She could then taper prednisone and stop it after
3 months since start. During follow-up, the patient
relapsed three times (February 2009, August 2010, and
September 2011). During each episode, platelet count was
<30 9 109/L with the presence of cutaneous bleedings;
the patient was treated again with prednisone, 0.5–1 mg/
kg/day, obtaining a transient CR, after the first and the
second episode, while after the third one, corticosteroid
therapy was ineffective. Due to the age of the patient
(65 years) and her poor compliance, splenectomy was
considered contraindicated. Moreover, we did not con-
sider rituximab and other immunosuppressants
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convenient for an old patient who was just given corticos-
teroids. Consequently, in December 2011, treatment with
eltrombopag was started at a dosage of 50 mg/day, then,
increased up to the maximum dosage of 75 mg/day. At
the seventh week of treatment, eltrombopag was sus-
pended because of high platelet count (650 9 109/L). A
week later, platelet count normalized (210 9 109/L). Sub-
sequently, the patient obtained a sustained CR off ther-
apy, without other treatments or rescue therapies, with a
platelet count ranging between 115 and 320 9 109/L (me-
dian 156 9 109/L). In July 2013, the patient came back to
our center, because of altered values of blood tests. In
particular, she presented microcytic anemia (Hb 8.9 gr/
dL, MCV 75 fL), normal number and differential count
of white blood cells, normal platelet level (118 9 109/L),
increased inflammation indexes (erythrocyte sedimenta-
tion rate 60, C reactive protein 6 mg/dL), and polyclonal
hypergammaglobulinemia. Neither iron deficiency nor
autoimmune hemolytic anemia were found. Liver and
spleen enlargement observed at the physical exam was
confirmed by a CT scan, which also showed subdiaphrag-
matic lymphoadenopathies (short- and long-axis diame-
ters <2 cm). Serologic evaluation for HIV, HCV, HBV
infections was negative. A bone marrow examination did
not show abnormalities; peripheral blood immunopheno-
type evaluation did not provide evidence of a monoclonal
B- or T-lymphocyte population; moreover, the patient
was negative for JAK2 mutation. A bone marrow biopsy
did not show either fibrosis, or a lymphoproliferative dis-
order. Therefore, at that time we could not formulate a
diagnosis. In October 2013, after 20 months of sustained
CR, the patient relapsed (platelet count 4 9 109/L).
Because of the previous response, eltrombopag was
restarted (50 mg/day), without concomitant corticos-
teroids administration. After 2 months of treatment, the
patient obtained again a CR (platelet count 164 9 109/L).
In January 2014, eltrombopag was suspended and the
patient reached a second sustained CR off treatment. In
the mean time, a further bone marrow immunophenotype
evaluation documented a clonal B-lymphocytic popula-
tion (CD20/CD38+, CD103, IgG-lambda restricted) and
a bone marrow biopsy showed poor infiltration of large
sized atypical lymphoid cells in the context of a large
number of reactive T lymphocytes. At immunohistochem-
istry evaluation, the atypical lymphoid cells were CD20
positive; BCL6 and CD10 were not evaluable. The evi-
dence of these atypical large B cells allowed a diagnosis of
aggressive B-cell lymphoma of probable splenic origin.
Then, the patient underwent six cycles of immune-che-
motherapy with rituximab, cyclophosphamide, vincristine,
prednisone (R-CVP) every 3 weeks from February to July
2014. At the end of the sixth cycle, she obtained a com-
plete remission according to Cheson criteria: negative CT/
PET-scan and bone marrow biopsy [3]. During the whole
period of immune-chemotherapy, the patient never
relapsed for ITP. In November 2015, a CT scan per-
formed for the presence of B symptoms (fever, joint pain,
and night sweats) documented a relapse of lymphoma
(splenomegaly and diffuse lymphoadenopathies). For this
reason, the patient underwent immune-chemotherapy
with rituximab and bendamustine for six planned courses.
At the most recent control (May 2016), she is in sus-
tained CR for ITP, which is persisting after 26 months
(platelet count 121 9 109/L). We cannot completely
exclude that treatment with corticosteroids and rituximab
which are part of the lymphoma therapy could help to
maintain the ITP sustained response. Partial remission of
the lymphoma has been documented by a CT scan.
Discussion
In this case report, eltrombopag was used as second-line
therapy for loss of response to corticosteroids. The patient
was treated for two short periods, obtaining a CR and
maintaining a sustained CR off therapy, lasting 20 and
26 months, respectively. In the last few years, literature
reports have shown the possibility of maintaining response
after discontinuation of TPO-RAs, in up to 10–40% of
patients treated either with romiplostim or eltrombopag
[4–10]. In particular, as regard as eltrombopag, Leven et al.
[4] described a case series in which 5/15 (33%) patients
could stop eltrombopag and maintained a sustained CR for
≥5 months off treatment. Gonzalez-Lopez et al. [8]
reported on the successful discontinuation of eltrombopag
on a pITP case series of 260 patients: 201 obtained a CR
and the rate of sustained response off therapy was 10% (26/
260). As regard as pathophysiological mechanisms underly-
ing this phenomenon, Ghadaki et al. [5] suggested that
TPO-RAs, increasing the exposure of immune system to
platelet antigens, may restore immune tolerance to plate-
lets, as similarly it is hypothesized for immune tolerance
induction in patients with hemophilia and inhibitory
alloantibodies to FVIII. Moreover, the TPO-RAs themselves
may have a direct effect on restoring normal T-regulatory
function [11].
Our patient relapsed after 20 months of sustained CR.
She was treated again with eltrombopag obtaining a second
sustained CR lasting 26 months. Therefore, she could safely
perform invasive procedures as bone marrow biopsy and
undergo immune-chemotherapy. Our experience is in
agreement with results of the “REPEAT” study from Bussell
et al. [12]. In this study, the authors explored the cyclic use
of eltrombopag (50 mg/day for 6 weeks, then 4 weeks off
treatment for three cycles) demonstrating that loss of
response occurred between cycles could be recovered in the
most part of patients (87% of responders to the first cycle)
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using the same TPO-RA. Data are also reported about the
use of TPO-RAs for the treatment of thrombocytopenia
related to hematologic, autoimmune, and infectious dis-
eases, or to chemotherapy [13–19]. In particular, the use of
eltrombopag in chronic lymphocytic leukemia (CLL) asso-
ciated ITP was described by different authors [13–15]: in
two cases, a CR was obtained and one patient could stop
the drug [13]; in one case, eltrombopag was successfully
used preoperatively to increase the platelet count to allow
laparoscopic splenectomy [14]; in one other case, eltrom-
bopag increased platelet count to normal range 13 days
after treatment start in a patient who presented recurrent
ITP associated to pulmonary hemorrhage [15]. Al-Nawakil
et al. [16] reported the use of romiplostim in four ITP
patients during the diagnostic phase or after diagnosis of
lymphomas: 3/4 patients obtained a response. Gudbrands-
dottir et al. [17] reported the use of both TPO-RAs in a
series of patients affected by either pITP or by other disor-
ders; thirty-two cases were included in this study: 15
received TPO-RAs for pITP, 7 for secondary ITP (CLL,
LES, Evans syndrome, HIV infection, and celiac disease),
10 for nonimmune thrombocytopenia (chemotherapy,
acute myeloid leukemia, myelodysplastic syndrome, heredi-
tary spherocytosis, and suspected chemically induced
thrombocytopenia). Response was obtained in 59% of pITP
patients, in 57% of secondary ITP, and in 40% of patients
with nonimmune thrombocytopenia. The use of TPO-RAs
in lymphoproliferative disorders has been reported even in
one randomized study by Moskowitz et al. [18]: a first gen-
eration TPO-RA (PEG-MGDF) was randomly introduced
in the chemotherapeutic regimen ICE for treatment of 41
patients affected by refractory/relapsed diffuse large-cell
lymphomas (DLCL). This therapy could improve platelet
count in patients with thrombocytopenia treatment related
and consequently allowed to keep dose-intensity
chemotherapy. Demeter et al. [19] described a case of a
patient, belonging to Yehova’s witnesses, affected by mantle
cell lymphoma, treated with intensive chemotherapy
(Hyper CVAD): on day 13 from the start of chemotherapy,
a severe thrombocytopenia developed associated with gas-
trointestinal bleeding, but the patient did not accept plate-
let transfusions. A single dose of 1000 mcg of romiplostim
was given obtaining a quick normalization of the platelet
count. In all these reports, the authors highlighted the ben-
efits of TPO-RAs use, either for their efficacy on increasing
platelet count to perform invasive procedures and
chemotherapy or for their safety profile in patients who are
severely immunosuppressed because of the underlying dis-
ease or concomitant therapies. TPO-RAs are efficacious in
the treatment of pITP, and in some cases, it is possible to
reach a sustained response after discontinuation. Moreover,
in case of relapse, treatment with the previously used TPO-
RA could induce a further response. TPO-RAs can be used
not only for pITP, but also in case of thrombocytopenia
related to other disorders or chemotherapy. In this subset
of patients, the response rate is high, confirming the effi-
cacy of TPO-RAs also in secondary immune or nonim-
mune thrombocytopenia.
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